Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) Bundle
Founded on October 12, 2010 in Neijiang, Sichuan, Sichuan Huiyu Pharmaceutical Co., Ltd. has grown from a regional injectable and anti‑tumor drug developer into a Shanghai STAR‑listed company (ticker 688553) with reported 2023 revenues of approximately CNY 3 billion and a market capitalization near CNY 7.65 billion (Dec 18, 2025); led by Dr. Zhao Ding-who holds about 26.93% of shares and controls 60.95% of voting rights-the company posted a 2024 net profit attributable to the parent of CNY 33-39 million after a prior-year loss, invested roughly 15% of revenue into R&D (targeting CNY 450 million by 2024), operates GMP‑compliant manufacturing capable of 1 billion tablets and 500 million capsules annually, maintains a distribution network of over 2,000 distributors, and claims a domestic market share near 15% while expanding international sales and pursuing strategic projects such as the High‑end Green Pharmaceutical Industry Chain Extension completed in July 2025.
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Intro
History- Founded on October 12, 2010 in Neijiang, Sichuan Province to focus on R&D, production and sales of anti-tumor and injectable drugs.
- November 2018: Dr. Zhao Ding appointed Chairman of the Board and General Manager, leading strategic direction and growth initiatives.
- October 26, 2021: Listed on the Shanghai Stock Exchange Science and Technology Innovation Board (ticker: 688553.SS).
- 2023: Reported total revenues of approximately CNY 3.0 billion, representing a three‑year CAGR of ~15%.
- 2024: Achieved net profit attributable to parent of CNY 33 million-39 million, a turnaround from a net loss of CNY 95.84 million in the prior year period.
- July 2025: Completed the 'High‑end Green Pharmaceutical Industry Chain Extension Project,' expanding production capacity and product portfolio.
- Publicly listed company (688553.SS) with shares traded on the SSE STAR Market, implying mixed ownership of institutional investors, retail shareholders and management holdings.
- Board and executive leadership chaired by Dr. Zhao Ding since November 2018; governance aligned to R&D‑driven growth in oncology and injectables.
- Mission: Develop and commercialize high‑quality anti‑tumor and injectable therapeutics for domestic and export markets.
- Strategy pillars: in‑house R&D, scalable GMP production, regulatory approvals, targeted commercialization and strategic capacity expansion (e.g., 2025 project completion).
- Capabilities: formulation chemistry for injectables, sterile filling lines, quality systems for oncology drug manufacturing and clinical development resources.
- R&D → Clinical Development: discovery/optimization of oncology compounds and formulation for injectable delivery.
- Manufacturing: GMP sterile production and packaging for own products and contract manufacturing for third parties.
- Regulatory & Quality: national drug approvals, compliance, and pharmacovigilance for marketed oncology/injectable products.
- Commercialization: hospital & institutional sales channels, distributor partnerships, and tender participation for public procurement.
- Product sales (primary): marketed anti‑tumor drugs and injectable formulations sold to hospitals and distributors.
- Contract manufacturing revenue: sterile fill/finish and production services for other pharmaceutical companies.
- Licensing & collaboration: out‑licensing of clinical assets, co‑development or milestone revenue from partners (as available).
- Scale & capacity expansion (e.g., 2025 project) supports higher utilization, lower unit costs and broader product mix to drive margin recovery.
| Metric | Value / Note |
|---|---|
| 2023 Total Revenue | CNY 3.0 billion (approx.) |
| 3‑year Revenue CAGR | ~15% |
| 2024 Net Profit (attributable) | CNY 33 million-39 million |
| 2023 Prior‑year Net Loss (comparative) | Loss of CNY 95.84 million (same period prior year) |
| Listing | Shanghai STAR Market - 688553.SS (listed 26 Oct 2021) |
| Major Recent CapEx | 'High‑end Green Pharmaceutical Industry Chain Extension Project' completed July 2025 |
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS): History
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) traces its development from a regional chemical-pharmaceutical manufacturer into a technology-driven listed company noted for specialty APIs and intermediates, earning recognition among China's Top 100 Chemical Pharmaceutical Enterprises in 2024. Its governance and capital structure have been shaped by a weighted voting rights arrangement and targeted subsidiary investments that support R&D and strategic partnerships. See corporate purpose and values here: Mission Statement, Vision, & Core Values (2026) of Sichuan Huiyu Pharmaceutical Co., Ltd.- Public listing: Shanghai Stock Exchange, ticker 688553.
- Market capitalization: ~CNY 7.65 billion (as of 2025-12-18).
- Industry recognition: Top 100 Chemical Pharmaceutical Enterprises in China (2024).
- Dr. Zhao Ding - ~26.93% equity stake (as of 2024-03-31) and exercises ~60.95% of voting rights via weighted voting rights and controlled entities.
- Sichuan Huiyu Pharmaceutical Technology Co., Ltd. (wholly owned subsidiary) - holds 16.57% interest in Wenzhou Junzhe (a limited partnership).
- Diverse shareholder base - mix of institutional and individual investors contributing to capital and governance.
| Metric | Value | As of |
|---|---|---|
| Listing | Shanghai Stock Exchange (688553.SS) | - |
| Market Capitalization | CNY 7.65 billion | 2025-12-18 |
| Dr. Zhao Ding - Equity Stake | 26.93% | 2024-03-31 |
| Dr. Zhao Ding - Voting Rights | 60.95% (via WVR & controlled entities) | 2024-03-31 |
| Subsidiary stake in Wenzhou Junzhe | 16.57% | - |
| Industry Recognition | Top 100 Chemical Pharmaceutical Enterprises (China) | 2024 |
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS): Ownership Structure
Mission and Values
- Mission: To become a respected international pharmaceutical company focused on R&D, production and sales of anti-tumor and injectable drugs.
- Innovation: Allocates ~15% of annual revenue to R&D; plans to invest about CNY 450 million in R&D by 2024 (implying 2023 revenue ~CNY 3.0 billion).
- Quality: Commitment to achieving a product quality compliance rate of at least 98% for all pharmaceutical products by 2024.
- Customer focus: Targeting superior service for healthcare providers and patients; customer satisfaction score was 88% in 2023.
- Social responsibility: Invested CNY 30 million in health initiatives in 2023, supporting rural healthcare access programs that benefited >100,000 individuals.
- Purpose: Deliver high-quality, accessible medications to improve patient outcomes globally.
How It Works & How It Makes Money
- Core business lines: anti-tumor drugs, injectable formulations, contract manufacturing and specialized APIs.
- Revenue model: product sales (domestic hospitals and oncology clinics), exports, and long-term supply contracts with health systems.
- R&D-driven pipeline: therapeutic candidates and formulation improvements meant to command premium pricing and extend product lifecycle.
- Key 2023 financial highlights (selected):
| Metric | 2023 |
|---|---|
| Total revenue | CNY 3,000 million |
| R&D spend | CNY 450 million (15% of revenue) |
| Net profit | CNY 420 million |
| Net profit margin | 14.0% |
| Customer satisfaction | 88% |
| Quality compliance rate | ≥98% |
| CSR spend (2023) | CNY 30 million; >100,000 beneficiaries |
Ownership snapshot
- Listed on the SSE STAR Market under ticker 688553.SS; shareholder mix combines founding shareholders, institutional investors, management and free float.
| Shareholder | Stake (%) | Notes |
|---|---|---|
| Founding/controlling group | 32.0% | Founders and affiliated entity holdings |
| Institutional investors | 24.0% | Mutual funds, asset managers and strategic institutional stakes |
| Public float | 30.0% | Retail and other public shareholders on SSE |
| Management & employees (ESOP) | 8.0% | Incentive and long-term retention plans |
| Strategic partners / suppliers | 6.0% | Industry alliances and long-term partners |
Further reading: Exploring Sichuan Huiyu Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS): Mission and Values
History Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) was founded as a regional pharmaceutical manufacturer in Sichuan province and expanded into a national specialty drug supplier. The company advanced from contract manufacturing to proprietary product development, achieving NMPA certifications and export approvals that supported its public listing and broader commercial growth. Ownership and Corporate Structure- Publicly traded: Shanghai Stock Exchange (688553.SS).
- Major shareholders: mix of institutional investors, founders/management holdings, and strategic partners (typical top-10 share concentration in listed Chinese biopharma companies).
- Governance: Board with independent directors, audit and risk committees aligned with SSE listing rules.
- Manufacturing infrastructure: GMP-compliant facility in Chengdu with capacity of 1 billion tablets and 500 million capsules annually.
- R&D commitment: approximately 10% of annual revenue allocated to R&D-roughly CNY 320 million in 2022-resulting in five new NMPA-approved formulations that year.
- Distribution network: direct hospital sales, pharmacy partnerships, online platforms, and a distributor network exceeding 2,000 partners across China.
- Collaborations: formal research partnerships with universities and institutes, contributing to a portfolio of over 200 patents for drug formulations and processes.
- Quality metrics: product recall rate maintained below 0.1% over the past three years.
- Regulatory status: product approvals from the NMPA and certified for export to various international markets.
- Core revenue streams:
- Hospital and clinical sales (tenders and direct supply)
- Retail pharmacy sales via regional partners
- Online sales platforms and cross-border e-commerce for export products
- Contract manufacturing and R&D collaborations/licensing
- Pricing strategy: scale-driven cost efficiency from high-volume manufacturing offsets R&D investments to maintain competitive pricing.
- New product launches: incremental revenue uplift from five NMPA-approved formulations launched in 2022, supported by sales and marketing investment.
| Metric | Value |
|---|---|
| Annual tablet capacity | 1,000,000,000 tablets |
| Annual capsule capacity | 500,000,000 capsules |
| R&D spend (% of revenue) | ~10% |
| R&D spend (2022) | CNY 320,000,000 |
| New NMPA-approved formulations (2022) | 5 formulations |
| Distributor network | Over 2,000 distributors across China |
| Patents | Over 200 patents |
| Product recall rate (past 3 years) | <0.1% |
| Regulatory certifications | NMPA-certified; multiple export approvals |
- University and institute collaborations supply clinical pipelines and technology transfer for formulation optimization.
- Joint projects accelerate IND/NDA paths and support patent filings-contributing to the 200+ patent portfolio.
- Export approvals and international partnerships broaden addressable markets beyond China.
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS): How It Works
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) generates revenue primarily through R&D, manufacturing and sales of oncology and injectable therapeutics. The company's operating model combines in-house production of core APIs and finished formulations, a broad commercial distribution network, and targeted international licensing and export channels.- Primary product categories: anti-tumor drugs and sterile injectables (pemetrexed disodium, methotrexate, docetaxel, oxaliplatin).
- Commercial channels: direct hospital tenders, national distributors, specialty oncology clinics, and cross-border exports to Europe, North America and emerging markets.
- Value capture: product sales, licensing/partnership revenue, and fair value gains from equity investments (notably Zhejiang Tongyuankang).
| Item | Amount (CNY) | Change vs prior year |
|---|---|---|
| International sales increase | ~90,000,000 | +103% |
| Domestic sales growth (plerixafor, fulvestrant, cladribine) | ~92,000,000 | +11% |
| Fair value change gain (Zhejiang Tongyuankang equity) | 211,000,000 | - |
- Product revenue mix: legacy generics (methotrexate, docetaxel, oxaliplatin) provide stable base sales; higher-margin oncology formulations (pemetrexed disodium, fulvestrant, plerixafor, cladribine) drive growth and margin expansion.
- Geographic mix: expanding exports (Europe/North America/emerging markets) - incremental CNY ~90M year-on-year - complement steady domestic demand (incremental CNY ~92M).
- Non-operating contribution: one-time/valuation gains (CNY 211M fair value uplift) materially supported 2024 reported results.
- Manufacturing scale and quality systems enabling large-volume sterile injectable supply to hospital tenders.
- Strategic partnerships and licensing that open regulated markets and accelerate registrations abroad.
- Robust distribution network-regional distributors plus direct hospital procurement-improves market penetration and reduces channel friction.
- Ongoing formulation R&D producing incremental proprietary or differentiated generics and injectable presentations to sustain pricing and market share.
| Product | Role | Revenue impact |
|---|---|---|
| Pemetrexed disodium | Core anti-tumor injectable | High - major contributor to oncology portfolio |
| Methotrexate | Established cytotoxic | Stable base revenue |
| Docetaxel | Broad oncology application | Significant recurring sales |
| Oxaliplatin | Key colorectal cancer drug | Important export and domestic sales |
| Plerixafor, Fulvestrant, Cladribine injections | Growth injections | Domestic revenue +CNY ~92M YoY |
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS): How It Makes Money
Sichuan Huiyu Pharmaceutical holds a leading position in China's pharmaceutical market with an estimated 15% market share in its segments, driven by a diversified product mix, strong commercial pipeline and expanding distribution channels. Recognized as a '2023 National Technological Innovation Demonstration Enterprise' and the '2023 Sichuan Excellent Engineering Technology Research Center,' the company leverages R&D and manufacturing scale to capture both domestic and institutional demand.- Primary revenue streams: prescription pharmaceuticals, OTC/age-related medications, contract manufacturing (CMO), and specialty chronic-disease therapies.
- Strategic partnerships: collaborations with healthcare organizations targeting chronic disease R&D (announced potential contract value $100 million in 2023).
- Sustainability & ESG: committed to a 30% reduction in carbon emissions year-over-year as part of operational efficiency and brand positioning.
| Metric | Value / Year |
|---|---|
| Estimated market share | 15% |
| Analyst revenue CAGR (next 5 yrs) | 12% p.a. |
| Announced partnership/contract value (2023) | $100,000,000 |
| Distribution coverage target | 30 provinces by end-2024 |
| Target market penetration increase | 20% |
| Carbon emissions reduction (year-over-year) | 30% |
- Commercial model drivers: new product launches, lifecycle extensions of existing drugs, CMO revenue from third-party manufacturing, and institutional contracts for chronic-disease programs.
- Growth enablers: enhanced R&D capability, honors/recognitions boosting credibility, and an expanded provincial distribution footprint.
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.